* Study found binimetinib significantly extended median
progression-free survival, at 2.8 months, versus 1.5 months
observed with dacarbazine
The post BRIEF-Array Biopharma presents full results from Phase 3 NEMO study appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Study found binimetinib significantly extended median
progression-free survival, at 2.8 months, versus 1.5 months
observed with dacarbazine
The post BRIEF-Array Biopharma presents full results from Phase 3 NEMO study appeared first on NASDAQ.